AP2034A - Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof. - Google Patents

Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof.

Info

Publication number
AP2034A
AP2034A APAP/P/2003/002795A AP2003002795A AP2034A AP 2034 A AP2034 A AP 2034A AP 2003002795 A AP2003002795 A AP 2003002795A AP 2034 A AP2034 A AP 2034A
Authority
AP
ARIPO
Prior art keywords
proteins
inhibition
therapeutic
derived
biological activity
Prior art date
Application number
APAP/P/2003/002795A
Other versions
AP2003002795A0 (en
Inventor
Beate Kehrel
Martin Brodde
Original Assignee
Hamburger Stiftung Zur Forderung Wissenschaft
Mera Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10051983A external-priority patent/DE10051983A1/en
Priority claimed from DE2001148624 external-priority patent/DE10148624A1/en
Application filed by Hamburger Stiftung Zur Forderung Wissenschaft, Mera Gmbh filed Critical Hamburger Stiftung Zur Forderung Wissenschaft
Publication of AP2003002795A0 publication Critical patent/AP2003002795A0/en
Application granted granted Critical
Publication of AP2034A publication Critical patent/AP2034A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)

Abstract

The present invention relates to substances, that inhibit the binding of oxidized proteins to CD36 or that inhibit the functions of CD36 induced by the interaction of CD36 with oxidized proteins, and their use as a medicament for humans and animals.
APAP/P/2003/002795A 2000-10-20 2001-10-19 Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof. AP2034A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10051983A DE10051983A1 (en) 2000-10-20 2000-10-20 Medicaments useful e.g. for preventing thrombosis, inhibiting transplant rejection or treating chronic inflammatory reactions comprises agents inhibiting binding of oxidized proteins to CD36,
DE2001148624 DE10148624A1 (en) 2001-10-02 2001-10-02 Medicaments useful e.g. for preventing thrombosis, inhibiting transplant rejection or treating chronic inflammatory reactions comprises agents inhibiting binding of oxidized proteins to CD36,
PCT/EP2001/012129 WO2002032445A2 (en) 2000-10-20 2001-10-19 Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof

Publications (2)

Publication Number Publication Date
AP2003002795A0 AP2003002795A0 (en) 2003-06-30
AP2034A true AP2034A (en) 2009-08-28

Family

ID=26007431

Family Applications (2)

Application Number Title Priority Date Filing Date
APAP/P/2003/002795A AP2034A (en) 2000-10-20 2001-10-19 Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof.
AP2009004857A AP2781A (en) 2000-10-20 2001-10-19 Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechansim, from the use of these porteins or from the inhibition thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AP2009004857A AP2781A (en) 2000-10-20 2001-10-19 Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechansim, from the use of these porteins or from the inhibition thereof

Country Status (13)

Country Link
EP (2) EP1328289B1 (en)
JP (1) JP4881535B2 (en)
AP (2) AP2034A (en)
AT (1) ATE406908T1 (en)
AU (1) AU2002215032A1 (en)
CA (1) CA2453140C (en)
CY (1) CY1110418T1 (en)
DE (1) DE50114289D1 (en)
DK (1) DK1328289T3 (en)
ES (1) ES2307662T3 (en)
OA (1) OA12431A (en)
PT (1) PT1328289E (en)
WO (1) WO2002032445A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE531427T1 (en) * 2003-04-25 2011-11-15 Hamburger Stiftung Zur Foerderung Von Wissenschaft Und Kultur FIGHTING HI-VIRUS INFECTIONS WITH HUMAN BLOOD PLASMA OXIDIZED BY HYPOCHLOROUS ACID
EP3260127B1 (en) * 2005-09-16 2019-05-01 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method of treating cerebral ischemia
JP2010235447A (en) * 2007-07-30 2010-10-21 Igaku Seibutsugaku Kenkyusho:Kk Inflammatory cytokine inhibitors
DE102010043733A1 (en) 2010-11-10 2012-05-10 Oxprotect Gmbh Unloaded PEGylated liposomes for use as medicaments for the prophylaxis and therapy of hemorrhagic and thromboembolic disorders
DE102011003936A1 (en) 2011-02-10 2012-08-16 Oxprotect Gmbh Use of proteins / peptides that bind to GRP78 (BIP) in laboratory methods for monitoring platelet aggregation inhibitors
DE102011003944A1 (en) 2011-02-10 2012-08-16 Oxprotect Gmbh Detection and removal of misfolded proteins / peptides
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991010684A1 (en) * 1990-01-08 1991-07-25 Schering Corporation Oxidized variants of gm-csf

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819923A1 (en) * 1988-06-11 1989-12-21 Behringwerke Ag FIBRINE (OGEN) DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
AU7045291A (en) * 1989-10-06 1991-05-16 Beth Israel Hospital Association, The Novel oxidized lipoproteins and methods for their preparation
JPH05508159A (en) * 1990-07-18 1993-11-18 ザ　ベス　イスラエル　ホスピタル　アソシエイション How to treat viral infections using oxidized lipoproteins
EP0728019A4 (en) 1993-11-08 1999-07-07 Peptide Delivery Systems Pty L Labelled diagnostic compositions and methods of their use
RU2089179C1 (en) * 1995-12-14 1997-09-10 Закрытое акционерное общество "ВАМ" Stimulator of cytokin and hemopoietic factors production and a method of its using
EP1021728B8 (en) 1997-06-20 2008-04-23 Leuven Research & Development VZW Assays, antibodies, and standards for detection of oxidized and mda-modified low density lipoproteins
GB9806632D0 (en) * 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
EP1124985A4 (en) * 1998-11-06 2003-01-15 Univ Emory OXIDATION STRESS BIOMARKERS
DE10045047A1 (en) * 2000-09-12 2002-03-21 Beate Kehrel Medicament containing activated antithrombin III

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991010684A1 (en) * 1990-01-08 1991-07-25 Schering Corporation Oxidized variants of gm-csf

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAWSON DAVID W et al *

Also Published As

Publication number Publication date
AU2002215032A1 (en) 2002-04-29
JP2004511526A (en) 2004-04-15
OA12431A (en) 2006-04-19
CA2453140C (en) 2016-01-05
WO2002032445A2 (en) 2002-04-25
DK1328289T3 (en) 2008-12-15
CY1110418T1 (en) 2015-04-29
HK1057857A1 (en) 2004-04-23
PT1328289E (en) 2008-12-10
WO2002032445A3 (en) 2003-04-17
EP1328289B1 (en) 2008-09-03
CA2453140A1 (en) 2002-04-25
AP2781A (en) 2013-10-31
EP1994941A2 (en) 2008-11-26
EP1994941A3 (en) 2012-07-25
DE50114289D1 (en) 2008-10-16
EP1328289A2 (en) 2003-07-23
AP2003002795A0 (en) 2003-06-30
ATE406908T1 (en) 2008-09-15
JP4881535B2 (en) 2012-02-22
ES2307662T3 (en) 2008-12-01
AP2009004857A0 (en) 2009-06-30

Similar Documents

Publication Publication Date Title
TR200001203T2 (en) New compounds
YU97202A (en) Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
AU2001272735A1 (en) Novel physiologically active peptide and use thereof
HK1050993A1 (en) Combinations of a receptor tyrosine kinase inhibitor with alpha1-acidic glycoprotein binding compound
MY176938A (en) 3,5-disubstituted and 3,5,7-trisubstituted-3h-oxazolo and 3h-thiazolo[4,5-d] pyrimidin-2-one compounds and prodrugs thereof
WO2003030927A3 (en) Use of thymulin-like peptides for making pain-relieving medicines
AP2034A (en) Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof.
BR9913337A (en) Derivatives tan-1057
TR200103638T2 (en) IL-8 Receptor antagonists
IL156069A0 (en) Use of a substance which binds to sarp-1 receptor or influences the activity of endogenous sarp-1 in scleroderma
AU2251302A (en) Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2
WO2001064876A3 (en) Human schizophrenia gene
KR100488038B1 (en) Novel body care compound peptide salts with organ protective activity, methods for their preparation and use thereof in the treatment
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases
ATE554393T1 (en) DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH ADIPONECTIN RECEPTOR 2 (ADIPOR2).
ES2191776T3 (en) COMPOSITIONS CONTAINING BISMUTO AND ONE OR MORE ANTIMICROBIAL AGENTS, FOR THE PREVENTION AND TREATMENT OF GASTROINTESTINAL DISORDERS.
DK1196439T3 (en) Compounds exhibiting an antibiotic activity
BR0014831A (en) Therapeutic drug for refractory lesions, comprising a substance with human leukocyte elastase inhibitory activity
IL156144A0 (en) Novel therapeutic use of a thienylcyclohexylamine derivative
PT1233748E (en) ASSOCIATION OF RETINAL AND ALDEIDS WITH ANTIFUNGAL ACTIVITY
ES2166912T3 (en) COMPOSITIONS, WHICH INCLUDE BISMUTE AND ONE OR MORE ANTIMICROBIAL AGENTS, FOR THE TREATMENT AND PREVENTION OF GASTROINTESTINAL DISORDERS.
FR2846658B1 (en) PEPTIDES FOR THE PREVENTION, DIAGNOSIS AND TREATMENT OF ANIMAL AND / OR HUMAN LEPTOSPIROSIS.
WO2002088345A3 (en) Murine dnasex, medicament containing the same and non-human mammal comprising modified dnasex gene
FR2759586B1 (en) ANTI-CANCER TYPE DRUG COMPRISING AT LEAST AS THE ACTIVE INGREDIENT OF 1-ALPHA HYDROXYCALCIFEROL OR ALFACALCIDOL
WO2004005346A3 (en) Human nuclear hormone receptor